You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 17, 2025

Drug Sales Trends for HUMALOG KWIK


✉ Email this page to a colleague

« Back to Dashboard


Payment Methods and Pharmacy Types for HUMALOG KWIK (2022)

Revenues by Pharmacy Type

Pharmacy Type Revenues
MAIL-ORDER $234,862,784
INSIDE ANOTHER STORE $383,169,424
[disabled in preview] $1,063,833,368
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
MAIL-ORDER 199,828
INSIDE ANOTHER STORE 434,310
[disabled in preview] 1,141,755
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $81,748,275
MEDICARE $1,211,538,759
[disabled in preview] $388,578,543
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for HUMALOG KWIK
Drug Units Sold Trends for HUMALOG KWIK

Annual Sales Revenues and Units Sold for HUMALOG KWIK

These sales figures are drawn from a US national survey of drug expenditures
Drug Name Revenues (USD) Units Year
HUMALOG KWIK ⤷  Try for Free ⤷  Try for Free 2022
HUMALOG KWIK ⤷  Try for Free ⤷  Try for Free 2021
HUMALOG KWIK ⤷  Try for Free ⤷  Try for Free 2020
HUMALOG KWIK ⤷  Try for Free ⤷  Try for Free 2019
HUMALOG KWIK ⤷  Try for Free ⤷  Try for Free 2018
HUMALOG KWIK ⤷  Try for Free ⤷  Try for Free 2017
>Drug Name >Revenues (USD) >Units >Year

Market Analysis and Sales Projections for Humalog KwikPen

Last updated: December 31, 2024

Market Overview

Humalog KwikPen, developed by Eli Lilly and Company, is a rapid-acting insulin analog used for the treatment of type 1 and type 2 diabetes. Here’s a comprehensive analysis of its market and sales projections.

Global Insulin Market Context

The global insulin market, including short-acting insulins like Humalog, is expected to grow significantly over the next few years. The global short-acting insulin market is projected to reach USD 10,287.9 million by 2030, growing at a CAGR of 1.18% from 2021[3].

Humalog Market Segment

Humalog is one of the key players in the short-acting insulin market. As of 2021, the Humalog segment had a market value of USD 2,462.7 million and is projected to reach USD 1,966 million by 2030, although at a negative CAGR of -2.47% due to market dynamics and competition[3].

Recent Financial Performance

In the second quarter of 2024, worldwide Humalog revenue saw a significant increase of 43% compared to Q2 2023, reaching $631.6 million. This surge indicates strong demand and market acceptance of Humalog products[2].

Product Innovations and Approvals

Humalog 200 units/mL KwikPen

The introduction of the Humalog 200 units/mL KwikPen has been a significant innovation. Approved by both the European Commission and the U.S. FDA, this concentrated formulation delivers the same dose in half the volume of the traditional Humalog 100 units/mL KwikPen, requiring no dose conversions and allowing for fewer pen changes per month[4][5].

This product has been particularly beneficial for patients requiring higher daily doses of mealtime insulin, enhancing their ability to manage their blood sugar levels more effectively.

Regional Analysis

The market for short-acting insulins, including Humalog, is segmented by region:

  • North America: This region is a major market for Humalog, driven by high healthcare spending and a large diabetic population.
  • Asia-Pacific: This region is expected to grow rapidly due to increasing diabetes prevalence and improving healthcare infrastructure.
  • Europe: The European market benefits from the approval of Humalog 200 units/mL KwikPen, providing patients with more treatment options.
  • Middle-East & Africa: These regions are also seeing growth, although at a slower pace compared to other regions[3].

Growth Drivers and Challenges

Growth Drivers

  • Increasing Diabetes Prevalence: The global rise in diabetes cases drives the demand for insulin products like Humalog.
  • Product Innovations: The introduction of concentrated formulations like Humalog 200 units/mL KwikPen enhances patient convenience and glycemic control.
  • Strong Financial Performance: Recent revenue increases indicate robust market demand and acceptance[2][3].

Challenges

  • Market Competition: The insulin market is highly competitive, with other major players like Novo Nordisk and Sanofi.
  • CAGR Decline: The projected negative CAGR for Humalog from 2021 to 2030 suggests potential market saturation or increased competition[3].

Sales Projections

Short-Term Projections

For Q2 2024, Humalog revenue has already shown a 43% increase compared to the previous year, reaching $631.6 million. This trend is expected to continue, driven by the strong performance of Eli Lilly's portfolio, including Humalog[2].

Long-Term Projections

Despite the projected negative CAGR for Humalog specifically, the overall short-acting insulin market is expected to grow. However, Humalog's market value is anticipated to decline to USD 1,966 million by 2030 from USD 2,462.7 million in 2021. This decline is offset by the overall growth in the insulin market and the introduction of new products and formulations[3].

Key Takeaways

  • Strong Recent Performance: Humalog has seen significant revenue growth in recent quarters.
  • Product Innovations: The Humalog 200 units/mL KwikPen has enhanced patient convenience and glycemic control.
  • Regional Growth: The market is segmented by region, with North America and Asia-Pacific being key drivers.
  • Challenges: Market competition and a projected decline in CAGR for Humalog.

FAQs

What is Humalog KwikPen?

Humalog KwikPen is a rapid-acting insulin analog used for the treatment of type 1 and type 2 diabetes, developed by Eli Lilly and Company.

What is the significance of Humalog 200 units/mL KwikPen?

The Humalog 200 units/mL KwikPen delivers the same dose in half the volume of the traditional Humalog 100 units/mL KwikPen, requiring no dose conversions and allowing for fewer pen changes per month.

How has Humalog performed financially in recent quarters?

In Q2 2024, worldwide Humalog revenue increased by 43% compared to Q2 2023, reaching $631.6 million.

What are the growth drivers for Humalog?

Growth drivers include increasing diabetes prevalence, product innovations like the Humalog 200 units/mL KwikPen, and strong financial performance.

What challenges does Humalog face in the market?

Challenges include market competition from other insulin products and a projected decline in CAGR for Humalog from 2021 to 2030.

What are the regional segments for the Humalog market?

The market is segmented into North America, Asia-Pacific, Europe, and Middle-East & Africa.

Sources

  1. Coherent Market Insights: Insulin Lispro Market Size, Trends and Forecast to 2030.
  2. Eli Lilly Investor Relations: Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue.
  3. Spherical Insights: Short-Acting Insulin Market Size, Share | Statistics 2030.
  4. PR Newswire: European Commission Grants Marketing Authorisation to Humalog 200 units/ml KwikPen.
  5. PR Newswire: U.S. Food and Drug Administration Approves Humalog 200 units/mL KwikPen.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.